Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Schering Strengthens Presence In South Korea

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Bayer Schering Pharma plans to upgrade its current seventh position in South Korea's pharma market to become one of three leading multinational companies in coming years, Bayer execs told reporters at a Nov. 27 press conference in Seoul

You may also be interested in...



South Korean Government Moves To Produce Hospital Marketing Specialists To Raise Local Standards

SEOUL - On the heels of a recent government announcement that it will further strengthen the nation's biologics, medical devices and global health care areas, the Ministry for Health, Welfare and Family Affairs is moving to train and produce what it calls "hospital marketing specialists" from local universities

South Korean Government Moves To Produce Hospital Marketing Specialists To Raise Local Standards

SEOUL - On the heels of a recent government announcement that it will further strengthen the nation's biologics, medical devices and global health care areas, the Ministry for Health, Welfare and Family Affairs is moving to train and produce what it calls "hospital marketing specialists" from local universities

Venture Capitalist Sheds Light On Market, Funding Options – Bio Korea (Part 1 of 2)

OSONG, South Korea - Venture capitalists are seeing the biggest returns from technology platforms or single-project financing, Hui-Hsing Ma, venture partner with TVM Capital told Bio Korea attendees.

Related Content

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel